1. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Issue 10 (3rd October 2015) Authors: Kipps, Thomas J.; Eradat, Herbert; Grosicki, Sebastian; Catalano, John; Cosolo, Walter; Dyagil, Iryna S.; Yalamanchili, Sreeni; Chai, Akiko; Sahasranaman, Srikumar; Punnoose, Elizabeth; Hurst, Deborah; Pylypenko, Halyna Journal: Leukemia & lymphoma Issue: Volume 56:Issue 10(2015:Oct.) Page Start: 2826 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study*. Issue 1 (2nd January 2019) Authors: Robak, Tadeusz; Huang, Huiqiang; Jin, Jie; Zhu, Jun; Liu, Ting; Samoilova, Olga; Pylypenko, Halyna; Verhoef, Gregor; Siritanaratkul, Noppadol; Osmanov, Evgenii; Pereira, Juliana; Mayer, Jiri; Hong, Xiaonan; Okamoto, Rumiko; Pei, Lixia; Rooney, Brendan; van de Velde, Helgi; Cavalli, Franco Journal: Leukemia & lymphoma Issue: Volume 60:Issue 1(2019) Page Start: 172 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. Issue 1 (2nd January 2019) Authors: Robak, Tadeusz; Huang, Huiqiang; Jin, Jie; Zhu, Jun; Liu, Ting; Samoilova, Olga; Pylypenko, Halyna; Verhoef, Gregor; Siritanaratkul, Noppadol; Osmanov, Evgenii; Pereira, Juliana; Mayer, Jiri; Hong, Xiaonan; Okamoto, Rumiko; Pei, Lixia; Rooney, Brendan; van de Velde, Helgi; Cavalli, Franco Journal: Leukemia & lymphoma Issue: Volume 60:Issue 1(2019) Page Start: 172 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Issue 6 (3rd May 2021) Authors: Auner, Holger W.; Gavriatopoulou, Maria; Delimpasi, Sosana; Simonova, Maryana; Spicka, Ivan; Pour, Ludek; Dimopoulos, Meletios A.; Kriachok, Iryna; Pylypenko, Halyna; Leleu, Xavier; Doronin, Vadim; Usenko, Ganna; Hajek, Roman; Benjamin, Reuben; Dolai, Tuphan Kanti; Sinha, Dinesh Kumar; Venner, Ch... Journal: American journal of hematology Issue: Volume 96:Issue 6(2021) Page Start: 708 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. Issue 3 (29th December 2021) Authors: Delimpasi, Sosana; Mateos, Maria Victoria; Auner, Holger W.; Gavriatopoulou, Maria; Dimopoulos, Meletios A.; Quach, Hang; Pylypenko, Halyna; Hájek, Roman; Leleu, Xavier; Dolai, Tuphan Kanti; Sinha, Dinesh Kumar; Venner, Christopher P.; Benjamin, Reuben; Garg, Mamta Krishnan; Doronin, Vadim; Levy,... Journal: American journal of hematology Issue: Volume 97:Issue 3(2022) Page Start: E83 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Issue 11 (November 2018) Authors: Robak, Tadeusz; Jin, Jie; Pylypenko, Halyna; Verhoef, Gregor; Siritanaratkul, Noppadol; Drach, Johannes; Raderer, Markus; Mayer, Jiri; Pereira, Juliana; Tumyan, Gayane; Okamoto, Rumiko; Nakahara, Susumu; Hu, Peter; Appiani, Carlos; Nemat, Sepideh; Cavalli, Franco Journal: Lancet oncology Issue: Volume 19:Issue 11(2018) Page Start: 1449 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Issue 2 (February 2016) Authors: Chanan-Khan, Asher; Cramer, Paula; Demirkan, Fatih; Fraser, Graeme; Silva, Rodrigo Santucci; Grosicki, Sebastian; Pristupa, Aleksander; Janssens, Ann; Mayer, Jiri; Bartlett, Nancy L; Dilhuydy, Marie-Sarah; Pylypenko, Halyna; Loscertales, Javier; Avigdor, Abraham; Rule, Simon; Villa, Diego; Samoil... Journal: Lancet oncology Issue: Volume 17:Issue 2(2016:Feb.) Page Start: 200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Issue 10262 (14th November 2020) Authors: Grosicki, Sebastian; Simonova, Maryana; Spicka, Ivan; Pour, Ludek; Kriachok, Iryrna; Gavriatopoulou, Maria; Pylypenko, Halyna; Auner, Holger W; Leleu, Xavier; Doronin, Vadim; Usenko, Ganna; Bahlis, Nizar J; Hajek, Roman; Benjamin, Reuben; Dolai, Tuphan K; Sinha, Dinesh K; Venner, Christopher P; G... Journal: Lancet Issue: Volume 396:Issue 10262(2020) Page Start: 1563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Issue 3 (March 2020) Authors: Gisslinger, Heinz; Klade, Christoph; Georgiev, Pencho; Krochmalczyk, Dorota; Gercheva-Kyuchukova, Liana; Egyed, Miklos; Rossiev, Viktor; Dulicek, Petr; Illes, Arpad; Pylypenko, Halyna; Sivcheva, Lylia; Mayer, Jiri; Yablokova, Vera; Krejcy, Kurt; Grohmann-Izay, Barbara; Hasselbalch, Hans C; Kralov... Journal: Lancet Issue: Volume 7:Issue 3(2020) Page Start: e196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups. Issue 6 (20th December 2020) Authors: Gisslinger, Heinz; Klade, Christoph; Georgiev, Pencho; Krochmalczyk, Dorota; Gercheva-Kyuchukova, Liana; Egyed, Miklos; Rossiev, Viktor; Dulicek, Petr; Illes, Arpad; Pylypenko, Halyna; Sivcheva, Lylia; Mayer, Jiri; Yablokova, Vera; Krejcy, Kurt; Hasselbalch, Hans C.; Kralovics, Robert; Kiladjian,... Other Names: collaborator. Journal: HemaSphere Issue: Volume 4:Issue 6(2020) Page Start: e485 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗